A guide to immunotherapy for COVID-19
FL van de Veerdonk, E Giamarellos-Bourboulis… - Nature medicine, 2022 - nature.com
Immune dysregulation is an important component of the pathophysiology of COVID-19. A
large body of literature has reported the effect of immune-based therapies in patients with …
large body of literature has reported the effect of immune-based therapies in patients with …
Immunomodulation as treatment for severe coronavirus disease 2019: a systematic review of current modalities and future directions
EA Meyerowitz, P Sen, SR Schoenfeld… - Clinical Infectious …, 2021 - academic.oup.com
In severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, viral load
peaks early and declines quickly after symptom onset. Severe coronavirus disease 2019 …
peaks early and declines quickly after symptom onset. Severe coronavirus disease 2019 …
Immune immunomodulation in coronavirus disease 2019 (COVID-19): strategic considerations for personalized therapeutic intervention
We are learning that the host response to severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection is complex and highly dynamic. Effective initial host defense in the …
(SARS-CoV-2) infection is complex and highly dynamic. Effective initial host defense in the …
Immunomodulation for severe COVID-19 pneumonia: the state of the art
Y Zhang, Y Chen, Z Meng - Frontiers in immunology, 2020 - frontiersin.org
COVID-19 has become a worldwide pandemic caused by the novel coronavirus named
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Severe cases of COVID-19 …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Severe cases of COVID-19 …
Immunotherapy of COVID-19: inside and beyond IL-6 signalling
G Zizzo, A Tamburello, L Castelnovo, A Laria… - Frontiers in …, 2022 - frontiersin.org
Acting on the cytokine cascade is key to preventing disease progression and death in
hospitalised patients with COVID-19. Among anti-cytokine therapies, interleukin (IL)-6 …
hospitalised patients with COVID-19. Among anti-cytokine therapies, interleukin (IL)-6 …
Immunobiology and immunotherapy of COVID‐19: A clinically updated overview
A Esmaeilzadeh, R Elahi - Journal of cellular physiology, 2021 - Wiley Online Library
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a new member of the
coronavirus family that can cause coronavirus disease 2019 (COVID‐19). COVID‐9 has …
coronavirus family that can cause coronavirus disease 2019 (COVID‐19). COVID‐9 has …
Pharmaco-immunomodulatory therapy in COVID-19
The severe acute respiratory syndrome coronavirus 2 associated coronavirus disease 2019
(COVID-19) illness is a syndrome of viral replication in concert with a host inflammatory …
(COVID-19) illness is a syndrome of viral replication in concert with a host inflammatory …
COVID-19: immunopathogenesis and Immunotherapeutics
L Yang, S Liu, J Liu, Z Zhang, X Wan… - Signal transduction and …, 2020 - nature.com
The recent novel coronavirus disease (COVID-19) outbreak, caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), is seeing a rapid increase in infected …
respiratory syndrome coronavirus 2 (SARS-CoV-2), is seeing a rapid increase in infected …
Immune responses in mildly versus critically ill COVID-19 patients
H Nasrollahi, AG Talepoor, Z Saleh… - Frontiers in …, 2023 - frontiersin.org
The current coronavirus pandemic (COVID-19), caused by SARS-CoV-2, has had
devastating effects on the global health and economic system. The cellular and molecular …
devastating effects on the global health and economic system. The cellular and molecular …
[HTML][HTML] Adjunct immunotherapies for the management of severely ill COVID-19 patients
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). It has infected millions, with more than 275,000 fatal cases as …
coronavirus 2 (SARS-CoV-2). It has infected millions, with more than 275,000 fatal cases as …